➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Moodys
Baxter
Colorcon
McKinsey

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

RETAPAMULIN - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for retapamulin and what is the scope of patent protection?

Retapamulin is the generic ingredient in one branded drug marketed by Almirall and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Retapamulin has sixty-nine patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for RETAPAMULIN
International Patents:69
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 54
Clinical Trials: 16
Patent Applications: 528
DailyMed Link:RETAPAMULIN at DailyMed
Recent Clinical Trials for RETAPAMULIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
New York University School of MedicinePhase 3
GlaxoSmithKlinePhase 1
Agency for Healthcare Research and Quality (AHRQ)Phase 4

See all RETAPAMULIN clinical trials

Pharmacology for RETAPAMULIN

US Patents and Regulatory Information for RETAPAMULIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almirall ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Almirall ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Almirall ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for RETAPAMULIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1028961 SPC/GB07/061 United Kingdom   Start Trial PRODUCT NAME: RETAPAMULIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/390/001 20070524; UK EU/1/07/390/002 20070524; UK EU/1/07/390/003 20070524; UK EU/1/07/390/004 20070524
1028961 91372 Luxembourg   Start Trial 91372, EXPIRES: 20220524
1028961 SPC042/2007 Ireland   Start Trial SPC042/2007: 20080415, EXPIRES: 20220523
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKinsey
AstraZeneca
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.